<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d17" origId="Brimonidine"><sentence id="DrugDDI.d17.s0" origId="s0" text="Although specific drug interaction studies have not been conducted with ALPHAGAN? P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered."><entity id="DrugDDI.d17.s0.e0" origId="s0.p12" charOffset="144-159" type="drug" text="CNS depressants"/><entity id="DrugDDI.d17.s0.e1" origId="s0.p14" charOffset="161-168" type="drug" text="alcohol"/><entity id="DrugDDI.d17.s0.e2" origId="s0.p15" charOffset="170-182" type="drug" text="barbiturates"/><entity id="DrugDDI.d17.s0.e3" origId="s0.p16" charOffset="184-191" type="drug" text="opiates"/><entity id="DrugDDI.d17.s0.e4" origId="s0.p17" charOffset="193-202" type="drug" text="sedatives"/><entity id="DrugDDI.d17.s0.e5" origId="s0.p19" charOffset="207-218" type="drug" text="anesthetics"/><pair id="DrugDDI.d17.s0.p0" e1="DrugDDI.d17.s0.e0" e2="DrugDDI.d17.s0.e1" interaction="false"/><pair id="DrugDDI.d17.s0.p1" e1="DrugDDI.d17.s0.e0" e2="DrugDDI.d17.s0.e2" interaction="false"/><pair id="DrugDDI.d17.s0.p2" e1="DrugDDI.d17.s0.e0" e2="DrugDDI.d17.s0.e3" interaction="false"/><pair id="DrugDDI.d17.s0.p3" e1="DrugDDI.d17.s0.e0" e2="DrugDDI.d17.s0.e4" interaction="false"/><pair id="DrugDDI.d17.s0.p4" e1="DrugDDI.d17.s0.e0" e2="DrugDDI.d17.s0.e5" interaction="false"/><pair id="DrugDDI.d17.s0.p5" e1="DrugDDI.d17.s0.e1" e2="DrugDDI.d17.s0.e2" interaction="false"/><pair id="DrugDDI.d17.s0.p6" e1="DrugDDI.d17.s0.e1" e2="DrugDDI.d17.s0.e3" interaction="false"/><pair id="DrugDDI.d17.s0.p7" e1="DrugDDI.d17.s0.e1" e2="DrugDDI.d17.s0.e4" interaction="false"/><pair id="DrugDDI.d17.s0.p8" e1="DrugDDI.d17.s0.e1" e2="DrugDDI.d17.s0.e5" interaction="false"/><pair id="DrugDDI.d17.s0.p9" e1="DrugDDI.d17.s0.e2" e2="DrugDDI.d17.s0.e3" interaction="false"/><pair id="DrugDDI.d17.s0.p10" e1="DrugDDI.d17.s0.e2" e2="DrugDDI.d17.s0.e4" interaction="false"/><pair id="DrugDDI.d17.s0.p11" e1="DrugDDI.d17.s0.e2" e2="DrugDDI.d17.s0.e5" interaction="false"/><pair id="DrugDDI.d17.s0.p12" e1="DrugDDI.d17.s0.e3" e2="DrugDDI.d17.s0.e4" interaction="false"/><pair id="DrugDDI.d17.s0.p13" e1="DrugDDI.d17.s0.e3" e2="DrugDDI.d17.s0.e5" interaction="false"/><pair id="DrugDDI.d17.s0.p14" e1="DrugDDI.d17.s0.e4" e2="DrugDDI.d17.s0.e5" interaction="false"/></sentence><sentence id="DrugDDI.d17.s1" origId="s1" text="Alpha-agonists, as a class, may reduce pulse and blood pressure."><entity id="DrugDDI.d17.s1.e0" origId="s1.p24" charOffset="6-14" type="drug" text="agonists"/></sentence><sentence id="DrugDDI.d17.s2" origId="s2" text="Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised."><entity id="DrugDDI.d17.s2.e0" origId="s2.p35" charOffset="29-34" type="drug" text="drugs"/><entity id="DrugDDI.d17.s2.e1" origId="s2.p36" charOffset="43-57" type="drug" text="beta-blockers"/><entity id="DrugDDI.d17.s2.e2" origId="s2.p43" charOffset="84-102" type="drug" text="anti-hypertensives"/><entity id="DrugDDI.d17.s2.e3" origId="s2.p45" charOffset="110-128" type="drug" text="cardiac glycosides"/><pair id="DrugDDI.d17.s2.p0" e1="DrugDDI.d17.s2.e0" e2="DrugDDI.d17.s2.e1" interaction="false"/><pair id="DrugDDI.d17.s2.p1" e1="DrugDDI.d17.s2.e0" e2="DrugDDI.d17.s2.e2" interaction="false"/><pair id="DrugDDI.d17.s2.p2" e1="DrugDDI.d17.s2.e0" e2="DrugDDI.d17.s2.e3" interaction="false"/><pair id="DrugDDI.d17.s2.p3" e1="DrugDDI.d17.s2.e1" e2="DrugDDI.d17.s2.e2" interaction="false"/><pair id="DrugDDI.d17.s2.p4" e1="DrugDDI.d17.s2.e1" e2="DrugDDI.d17.s2.e3" interaction="false"/><pair id="DrugDDI.d17.s2.p5" e1="DrugDDI.d17.s2.e2" e2="DrugDDI.d17.s2.e3" interaction="false"/></sentence><sentence id="DrugDDI.d17.s3" origId="s3" text="Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN? P in humans can lead to resulting interference with the IOP lowering effect."><entity id="DrugDDI.d17.s3.e0" origId="s3.p48" charOffset="0-25" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d17.s3.e1" origId="s3.p53" charOffset="89-98" type="drug" text="clonidine"/><pair id="DrugDDI.d17.s3.p0" e1="DrugDDI.d17.s3.e0" e2="DrugDDI.d17.s3.e1" interaction="true"/></sentence><sentence id="DrugDDI.d17.s4" origId="s4" text="No data on the level of circulating catecholamines after ALPHAGAN? P administration are available."/><sentence id="DrugDDI.d17.s5" origId="s5" text="Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines."><entity id="DrugDDI.d17.s5.e0" origId="s5.p82" charOffset="48-73" type="drug" text="tricyclic antidepressants"/></sentence></document>